HyperRAB, rabies immune globulin, receives FDA approval
by Press Release from Outbreak News Today on (#3FC0D)
Grifols, a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and immune globulin products for patients, has received approval from the U.S. Food & Drug Administration (FDA) for a new higher potency formulation of its HyperRAB(R) rabies immune globulin [human] for rabies postexposure prophylaxis (treatment of a person immediately after ["]
The post HyperRAB, rabies immune globulin, receives FDA approval appeared first on Outbreak News Today.